Description

22,23-Dihydroavermectin B(1A)-4''-(4-((4-(Ethyl(1,2,3,4-Tetrahydro-1,4-Dioxo-6-Phthalazinyl)Amino)Butyl)Amino)-4-Oxobutanoate) is a semi-synthetic derivative of the potent macrocyclic lactone, avermectin, engineered for enhanced stability and targeted biological activity. This compound is of significant interest for advanced research and development in the pharmaceutical and agrochemical sectors due to its potential as a high-value synthetic intermediate. It is primarily sought by R&D chemists and process development scientists working on novel antiparasitic agents, veterinary pharmaceuticals, and next-generation crop protection solutions.

Application

• Pharmaceutical Intermediate: Key building block in the synthesis of novel antiparasitic and anthelmintic drug candidates for human and veterinary medicine.
• Agrochemical Research: Used in the development of new, potent insecticides and acaricides with potential for improved environmental profiles.
• Biochemical Tool Compound: Employed in neuroscience and pharmacology research to study glutamate-gated chloride channels (GluCls) and other neurological targets.
• Process Chemistry & Scale-Up: Serves as a critical intermediate for process optimization and pilot-scale manufacturing of specialized active ingredients.
• Reference Standard: Utilized as a high-purity analytical standard for quality control and regulatory testing in related product manufacturing.

Basic Information

Product Name	22,23-Dihydroavermectin B(1A)-4''-(4-((4-(Ethyl(1,2,3,4-Tetrahydro-1,4-Dioxo-6-Phthalazinyl)Amino)Butyl)Amino)-4-Oxobutanoate)
CAS No.	122047-12-5
Molecular Formula	C52H73N5O13
Molecular Weight	976.17 g/mol
Synonyms	4''-O-(4-((4-(N-Ethyl-1,4-dioxo-1,2,3,4-tetrahydrophthalazin-6-yl)amino)butyl)carbamoyl)butanoyl-22,23-dihydroavermectin B1a; Avermectin B1a, 22,23-dihydro-, 4''-(4-((4-(ethyl(1,2,3,4-tetrahydro-1,4-dioxo-6-phthalazinyl)amino)butyl)amino)-4-oxobutanoate); Dihydroavermectin B1a phthalazinyl derivative; 22,23-Dihydroabamectin derivative; 4''-Deoxy-4''-(4-((4-(N-ethyl-1,4-dioxo-1,2,3,4-tetrahydrophthalazin-6-yl)amino)butyl)amino)-4-oxobutanoylavermectin B1a
EINECS	Contact for details

Quality Control

Our production of this advanced intermediate adheres to strict quality management protocols to ensure batch-to-batch consistency and high purity. Quality is verified through comprehensive analytical techniques including HPLC, NMR, and mass spectrometry. A detailed Certificate of Analysis (COA) is provided with each shipment, confirming identity, purity, and impurity profiles. We support development projects requiring compliance with cGMP guidelines for pharmaceutical intermediates.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and must be kept under anhydrous conditions. For long-term storage, consider storing under an inert atmosphere such as argon or nitrogen to prevent degradation.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Purity (HPLC)	≥ 95.0%
Single Maximum Impurity	≤ 2.0%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.